BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, January 28, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

April 6, 2009

View Archived Issues

Route of administration affects immunoglobulin use in immunodeficiency patients

Read More

Prostate cancer patients' survival predicted by radiologic progression improves with new vaccine

Read More

Novel b-Raf inhibitors claimed by Takeda

Read More

Statin-induced atherosclerotic plaque regression is more effective in women than men

Read More

Shanghai Hengrui discloses dipeptidyl peptidase IV inhibitors for diabetes

Read More

New heat shock protein 90 inhibitors investigated for effects in Alzheimer's disease

Read More

Synairgen reports preliminary findings from phase I trial of IFN-beta biomarker neopterin

Read More

First patient treated in Osiris' phase II stem cell trial for myocardial infarction

Read More

Intercell's Ixiaro approved in Europe to prevent Japanese encephalitis

Read More

Micromet receives milestone payment from Nycomed for MT-203

Read More

Gilead's phase III darusentan study for hypertension meets primary endpoints

Read More

Phase III results reported for Labopharm's twice-daily tramadol/acetaminophen combination

Read More

CV Technologies changes name to Afexa Life Sciences as part of rebranding plan

Read More

StemCells acquires Stem Cell Sciences

Read More

Enrollment completed in Depomed's phase III trial of Serada in menopausal hot flashes

Read More

Pfizer discontinues one of its phase III trials of Sutent in advanced breast cancer

Read More

InSite Vision and Nitten sign international licensing and distribution agreement for AzaSite

Read More

Novel Raf kinase inhibitors presented by GlaxoSmithKline

Read More

Orchid Research Laboratories presents novel monoamine oxidase inhibitors

Read More

Novel bile acid responsive receptor ligands discovered by Kalypsus

Read More

Novel mu-opioid receptor ligands developed by OSI Prosidion for the treatment of obesity

Read More

Low-molecular-weight allosteric inhibitor of luteinizing hormone receptor identified

Read More

Priligy reaches first market

Read More

Alnylam initiates phase I ALN-VSP trial in patients with liver cancer

Read More

FDA grants priority review for Genmab's Arzerra

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 26, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 27, 2026.
  • DNA mutations or genetic disorder concept art

    Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

    BioWorld Science

    Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

  • Brain with stroke illustration

    Brain-derived tau in blood predicts stroke severity and outcome

    BioWorld Science

    Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

  • Dice spelling out D-E-A-L-?, yes, no

    Muted and missing M&As: JPM deals absent in 2026

    BioWorld
    For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing